MannKind Corp
$ 4.11
5.66%
07 Aug - close price
- Market Cap 1,321,532,000 USD
- Current Price $ 4.11
- High / Low $ 4.15 / 3.85
- Stock P/E N/A
- Book Value -0.17
- EPS -0.16
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE N/A %
- 52 Week High 6.51
- 52 Week Low 2.23
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Analyst Target Price
$8.09
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-26 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 |
| Reported EPS | -0.06 | -0.02 | -0.05 | 0.03 | 0.05 | 0.04 | 0.03 | 0.04 | -0.01 | 0.04 | 0.0043 | 0.01 |
| Estimated EPS | -0.02 | 0.0067 | -0.01 | 0.01 | 0.08 | 0.06 | 0.04 | 0.03 | 0.01 | 0.03 | 0.01 | -0.02 |
| Surprise | -0.04 | -0.0267 | -0.04 | 0.02 | -0.03 | -0.02 | -0.01 | 0.01 | -0.02 | 0.01 | -0.0057 | 0.03 |
| Surprise Percentage | -200% | -398.5075% | -400% | 200% | -37.5% | -33.3333% | -25% | 33.3333% | -200% | 33.3333% | -57% | 150% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNKD
2026-08-05 20:11:57
MannKind Corporation reported strong Q2 2026 financial results with total revenues of $109.4 million, a 43% increase year-over-year. The company highlighted three major catalysts for future growth: the launch of Afrezza's pediatric indication, FDA approval of the Furoscix ReadyFlow™ autoinjector, and positive Phase 1b data for nintedanib DPI. These achievements are expected to fuel near-term growth and validate MannKind's diversification strategy.
2026-08-05 14:11:47
MannKind Corp is set to release its second-quarter earnings, with analysts anticipating a loss of 1 cent per share on revenue of $109.02 million, reflecting a significant year-over-year increase. The biopharmaceutical company is expected to capitalize on the recent FDA approval of FUROSCIX ReadyFlow, which analysts believe could be transformative for its revenue growth. Investors will be keenly watching for management commentary on the launch trajectory of ReadyFlow and updates on its dry powder inhaler pipeline.
2026-08-05 09:18:00
MannKind Corporation reported a 43% increase in Q2 2026 revenue, reaching $109.4 million, primarily due to the acquisition of scPharma and increased collaboration income. However, the company experienced a net loss of $19.0 million, an adverse swing from a profit of $0.7 million in Q2 2025, driven by higher launch spending for Furoscix and pediatric Afrezza, increased R&D, and significant financing costs. Key approvals for pediatric Afrezza and Furoscix ReadyFlow are expected to expand commercial opportunities, but investors are monitoring launch execution, margin pressures, and pipeline progress.
2026-08-03 15:43:20
MannKind Corporation's (MNKD) stock gained about 5% after the FDA approved its Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This makes Afrezza the first and only needle-free, inhaled mealtime insulin available for pediatric patients, who previously relied on injections or pumps. The approval was supported by positive data from the Phase 3 INHALE-1 study, demonstrating Afrezza's efficacy and patient satisfaction compared to traditional methods.
2026-07-31 14:49:26
MannKind Corp (MNKD) has a current financial score of 7.90, ranking 72 out of 384 in its industry, indicating weak financial status but high operating efficiency. The company recently reported a quarterly revenue of $90.17 million, marking a 15.08% year-over-year increase, and its net profit surged by 226.30% year-over-year. While key financial metrics like cash and equivalents, total assets, liabilities, and free cash flow are mentioned, the specific data values for these categories have not yet been disclosed by the company.
2026-07-31 14:40:25
Vanguard Capital Management LLC and its affiliates have reported a passive 5% ownership stake in MannKind Corp (MNKD), holding 15,450,421 shares as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating Vanguard's sole voting power over 2,281,029 shares and sole dispositive power over all its MannKind holdings. The investment is spread across various Vanguard funds and managed accounts, with no single underlying investor holding more than 5% through these positions.
